Microglial Activation in Young Adults With Autism Spectrum Disorder

Katsuki Suzuki, MD, PhD; Genichi Sugihara, MD, PhD; Yasuomi Ouchi, MD, PhD; Kazuhiko Nakamura, MD, PhD; Musami Futatsubashi, BS; Kiyokazu Takebayashi, MD, PhD; Yujirou Yoshikawa, MD, PhD; Kei Onuma, PhD; Kaori Matsumoto, MA; Kenji J. Tsuchiya, MD, PhD; Yasuhide Iwata, MD, PhD; Masatsugu Tsujii, MA; Toshirou Sugiyama, MD, PhD; Norio Mori, MD, PhD

Context: A growing body of evidence suggests that aberrant immunologic systems underlie the pathophysiologic characteristics of autism spectrum disorder (ASD). However, to our knowledge, no information is available on the patterns of distribution of microglial activation in the brain in ASD.

Objectives: To identify brain regions associated with excessively activated microglia in the whole brain, and to examine similarities in the pattern of distribution of activated microglia in subjects with ASD and control subjects.

Design: Case-control study using positron emission tomography and a radiotracer for microglia—[11C](R)-(1-[2-chlorophenyl]-N-methyl-N-[1-methylpropyl]-3-isoquinoline carboxamide) ([11C](R)-PK11195).

Setting: Subjects recruited from the community.

Participants: Twenty men with ASD (age range, 18-31 years; mean [SD] IQ, 95.9 [16.7]) and 20 age- and IQ-matched healthy men as controls. Diagnosis of ASD was made in accordance with the Autism Diagnostic Observation Schedule and the Autism Diagnostic Interview–Revised.

Main Outcome Measures: Regional brain [11C](R)-PK11195 binding potential as a representative measure of microglial activation.

Results: The [11C](R)-PK11195 binding potential values were significantly higher in multiple brain regions in young adults with ASD compared with those of controls (P < .05, corrected). Brain regions with increased binding potentials included the cerebellum, midbrain, pons, fusiform gyri, and the anterior cingulate and orbitofrontal cortices. The most prominent increase was observed in the cerebellum. The pattern of distribution of [11C](R)-PK11195 binding potential values in these brain regions of ASD and control subjects was similar, whereas the magnitude of the [11C](R)-PK11195 binding potential in the ASD group was greater than that of controls in all regions.

Conclusions: Our results indicate excessive microglial activation in multiple brain regions in young adult subjects with ASD. The similar distribution pattern of regional microglial activity in the ASD and control groups may indicate augmented but not altered microglial activation in the brain in the subjects with ASD.


Original Article

A

utism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by pervasive abnormalities in social interaction and communication and by repetitive and restricted behavioral patterns and interests. Autism spectrum disorders include autistic disorder, Asperger disorder, and pervasive developmental disorder not otherwise specified.¹ Recent population-based surveys²³ showing that ASD is more common than previously believed have aroused serious public concern worldwide. Although the neurobiologic basis for ASD remains poorly understood, a growing body of research⁴⁵ suggests that immune abnormalities are a contributing factor to the development of ASD. Several genetic studies link ASD with genes that are associated with various immune functions, including the HLA antigen⁶ and the major histocompatibility complex class III molecule, such as complement C4B.⁷⁸ Systemic abnormalities of the immune system have been one of the most common and long-standing reported findings in subjects with ASD.⁹¹⁰ Notably, increased production of cytokines (eg,
several studies have identified specific antibodies in control subjects, implying that there is a subset of ASD widely distributed and show substantial overlap with general conditions. Plasma cytokine levels in ASD subjects are generally increased, and cytokine expression profiles in brain tissues from the cerebellum, midfrontal, and cingulate gyrus obtained at autopsy from children and adults with ASD. Immunocytochemical examination revealed marked activation of microglia and astroglia. Microglial responses were diffusely distributed in the cortex and subcortical areas, as well as the cerebellum, and were present as microglial nodules or as part of a prominent accumulation of perivascular macrophages. More recently, Morgan and colleagues quantitatively assessed activated microglia in the dorsolateral prefrontal cortex of postmortem brains from children and adults with ASD. They found that the microglia were markedly or marginally activated in most cases examined. Transcriptomic analysis of the autistic brain by Voineagu and colleagues has shown the presence of 2 modules in the ASD brain: a neuronal module enriched for known autism susceptibility genes, including neuronal-specific factors, such as ataxin 2-binding protein 1, and a module enriched for immune genes and glial markers. The latter immune-glial module has a less pronounced genetic component and thus is most likely either a secondary phenomenon or the result of environmental factors. Despite the striking features of microglial activation in the pathogenesis of ASD, to our knowledge, there is no information on the patterns and characteristics of the distribution of microglial activation in the whole brain in ASD subjects.

To address this issue, we conducted a positron emission tomography (PET) analysis using the radiocarbon ([11C])-labeled (R)-1-[2-chlorophenyl]-N-methyl-N-[1-methylpropyl]-3-isquinoline carboxamide) ([11C]R)-PK11195), a radiotracer that specifically binds to activated microglia. This procedure permitted us to visualize the activated microglia in vivo in the whole brain. In this study, we initially determined the distribution of [11C]R)-PK11195 binding potential (BP) in the whole brain of young adults with ASD and then identified several brain regions associated with the activation of microglia. Subsequently, we compared the levels of [11C]R)-PK11195 BP in the identified brain regions. Because microglia may be prenatal in origin, and because ASD is typically diagnosed by 3 years of age, we hypothesized that the regional variability of the [11C]R)-PK11195 BP in the identified brain regions is similar between ASD and control subjects, whereas the magnitude of [11C]R)-PK11195BP in ASD subjects is greater than that of controls in all the regions. To test this hypothesis, we carefully recruited subjects with no history of epilepsy or medication because epileptic seizures and psychotropic drugs can influence the condition of microglial activation.

### METHODS

**SUBJECTS**

The ethics committees of the Hamamatsu University School of Medicine approved this study. Written informed consent was obtained from all subjects and their guardians after they had been provided a detailed explanation of the study procedures. Twenty men with ASD and 20 age- and IQ-matched typically developing male subjects participated in this study (Table 1). All subjects were right-handed and had an IQ of greater than 80. None of the subjects were tobacco smokers, and none were

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control (n = 20)</th>
<th>ASD (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>22.6 (5.3) [17.8-35.5]</td>
<td>23.3 (4.0) [18.6-31.9]</td>
</tr>
<tr>
<td>WAIS-III full IQ</td>
<td>102.8 (12.5) [81.0-131.0]</td>
<td>95.9 (16.7) [81.0-140.0]</td>
</tr>
<tr>
<td>ADI-R Social</td>
<td>NA</td>
<td>20.6 (5.1) [10.0-29.0]</td>
</tr>
<tr>
<td>ADI-R Communication</td>
<td>NA</td>
<td>15.2 (4.4) [8.0-24.0]</td>
</tr>
<tr>
<td>ADI-R Stereotype</td>
<td>NA</td>
<td>4.3 (2.2) [3.0-10.0]</td>
</tr>
<tr>
<td>ADOS Social</td>
<td>NA</td>
<td>6.4 (3.0) [4.0-11.0]</td>
</tr>
<tr>
<td>ADOS Communication</td>
<td>NA</td>
<td>6.2 (2.7) [2.0-13.0]</td>
</tr>
<tr>
<td>Y-BOCS</td>
<td>NA</td>
<td>1.0 (0.9) [0.0-3.0]</td>
</tr>
<tr>
<td>Y-BOCS</td>
<td>NA</td>
<td>21.2 (8.6) [3.0-34.0]</td>
</tr>
<tr>
<td>SCDQ-J Social</td>
<td>NA</td>
<td>11.0 (6.4) [0.0-28.0]</td>
</tr>
<tr>
<td>SCDQ-J Communication</td>
<td>NA</td>
<td>6.4 (3.0) [4.0-11.0]</td>
</tr>
<tr>
<td>SCDQ-J Stereotype</td>
<td>NA</td>
<td>4.3 (2.2) [3.0-10.0]</td>
</tr>
<tr>
<td>Faux Pas Test</td>
<td>NA</td>
<td>60.4 (12.0) [42.0-73.0]</td>
</tr>
</tbody>
</table>

**Table 1. Demographic Characteristics of the Subjects**

Abbreviations: ADI-R, Autism Diagnostic Interview-Revised; ADOS, Autism Diagnostic Observation Schedule; ASD, autism spectrum disorder; DCDDQ-J, Japanese version of the Developmental Coordination Disorder Questionnaire; NA, not applicable; WAIS-III, Wechsler Adult Intelligence Scale, third edition; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.

*All subjects were men.

\[P = .63.\]
taking any medication, including psychotropic drugs. All of them were physically healthy. At the time of scanning, all the subjects had no symptoms of inflammation and were not under stressful conditions. All the subjects with ASD were diagnosed by 2 trained child psychiatrists (K.N. and T.S.) according to the DSM-IV-TR.4 The ASD diagnosis was confirmed for all cases using the Autism Diagnostic Interview–Revised (ADI-R)39 and the Autism Diagnostic Observation Schedule (ADOS)39 module-4 by trained clinicians (K.J.T. and K.M., respectively). As a result, 15 of 20 ASD subjects were diagnosed as having autistic disorder and the remaining 5 were considered to have pervasive developmental disorder not otherwise specified on the basis of the ADOS scores, although all 20 subjects met the ADI-R criteria for autistic disorder. None of the ASD subjects was classified as having regressive autism, the classification of which was based on clinical characteristics using both parental reporting and answers to questions on the ADI-R regarding language loss (question 11) and social skills (question 25). The ASD subjects did not have any other psychiatric comorbidity disorders, as confirmed by the Structured Clinical Interview for DSM-IV Axis I disorders.60 In addition, they had no notable dysmorphism, neurocutaneous abnormalities, significant neurologic deficits, history of epileptic seizures, or disorders known to be associated with autism, such as fragile X syndrome, neurofibromatosis, or tuberous sclerosis. Fragile X syndrome was excluded by determining the CGG repeat number.

The brain, particularly in cortical subregions, is known to be sensitive to a partial volume effect that sometimes occurs during the measurement of small brain structures and that leads to an underestimation of tracer activity. In this study, we used the following previously described procedure to minimize the contribution of the partial volume effect.31,40 First, we adjusted the MRI voxel size to the PET voxel size 3-dimensionally using image-processing software (DrView; Asahi Kasei) on a Sun workstation (HyperSPARC ss-20; Sun Microsystems). Then, these reformatted MRIs with 3-dimensional scales and coordinates identical to those of the PET images were used as anatomic landmarks for the regions of interest (ROIs) setting. Subsequently, by referring to areas on the MRIs as anatomical landmarks, the ROIs were carefully drawn to avoid the involvement of either the sulci or ventricles. An investigator masked to the subject’s condition placed 3 ROIs over the bilateral cerebellar cortices, midbrain, and bilateral thalami on the MRIs. These ROIs were then transferred onto the corresponding dynamic [11C](R)-PK11195 images.

To assess activated microglial density in the brain, we analyzed the [11C](R)-PK11195 time-activity curves (TACs) on the basis of a simplified reference tissue model46,67 because the regional brain [11C](R)-PK11195 BP (a ratio of binding and dissociation rate constants, k5/k1) estimated by the simplified reference tissue model is reported to correlate with the magnitude of microglial activity.33,40 Because the decrease of TACs was sharpest in the cerebellar ROI among the 3 ROIs examined in the control group, we assumed that the specific binding would be the least in this region. A normalized input curve was first created by averaging the TACs from the ROIs placed over the bilateral cerebellar cortices in the control group. Then, the normalized mean input curve was used as the reference input function of the simplified reference tissue model in the ASD and control subjects because a desirable reference region free from specific binding was not evident in the ASD subjects.

Using biomedical imaging software (PMOD, version 3.0; PMOD Technologies), we constructed whole-brain parametric maps of the [11C](R)-PK11195 BP for the subsequent voxel-based analysis using Statistical Parametric Mapping software (SPM5; http://www.fil.ion.ucl.ac.uk/spm). The [11C](R)-PK11195 BP maps were normalized to the Montreal Neurological Institute space, as defined by the MRI T1 template implemented in SPM5. The extracerebral structures were then masked by demarcating cerebral regions on spatially normalized MRIs. Finally, the normalized and masked BP maps were smoothed with an 8-mm full-width at half maximum gaussian filter.

In addition to the voxel-based analysis, which is suitable for an exploratory examination of altered tracer distribution in the brain, we performed a volume of interest (VOI)–based analysis because it enabled us to generate quantitative differences in [11C](R)-PK11195 BP in specific regions. For this purpose, we placed additional spherical VOIs of 3-mm radius, which centered on the peak voxel derived from the results of the voxel-based analysis, on [11C](R)-PK11195 BP maps for each of the subjects. The VOIs selected were the bilateral cerebellum, brainstem, splenium of the corpus callosum, bilateral fusiform gyrus, bilateral superior temporal gyrus, and the bilateral anterior cingulate, bilateral orbitofrontal, left midfrontal, and right parietal cortices. Averaged [11C](R)-PK11195 BP values for each VOI were obtained in the ASD and control groups.

VOXEL-BASED MORPHOMETRY

To investigate possible differences in brain structure between the ASD and control groups, we conducted voxel-based morphometry. For this purpose, we used a 3-T MRI scanner (Signa Excite;
General Electric Medical Systems) to obtain T1-weighted volumetric images scanned by the inversion recovery-prepared fast spoiled gradient recalled acquisition protocol as follows: repetition time = 11.0 milliseconds, echo time = 5.0 milliseconds, preparation time = 450 milliseconds, flip angle 20°, number of excitations = 1, field of view = 24.0 cm, matrix = 256 × 256, auto-zero-fill interpolation = 512, location per slab = 160, slice thickness = 1.2 mm, and voxel size = 0.94 × 0.94 × 1.2 mm. The T1-weighted volumetric images were analyzed using the VBM5.1 toolbox (http://www.fil.ion.ucl.ac.uk/spm/ext/) implemented in SPM5 with the default parameters. Estimates of the absolute gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF) volumes were obtained after the automatic brain segmentation procedure had been carried out by VBM5.1. The total intracranial volume was calculated as the sum of the volumes of the GM, WM, and CSF.

STATISTICAL ANALYSIS

The demographic and clinical variables of the ASD and control groups were compared by the unpaired t test using statistical software (PASW Statistics version 18; SPSS Japan Inc.). The level of statistical significance was set at P < .05.

The voxel-based analyses of the [11C](R)-PK11195 BP maps were conducted using SPM5. For the SPM5 analysis of the [11C](R)-PK11195 BP maps, between-group comparisons were performed to explore regional differences in the [11C](R)-PK11195 BP using the t test for each voxel without a proportional scaling of the [11C](R)-PK11195 BP maps. We also performed exploratory correlation analyses between the regional changes in [11C](R)-PK11195 BP values and the severity of clinical features in ASD subjects using SPM5. The scores on the ADOS, ADI-R, Faux Pas Test, Yale-Brown Obsessive Compulsive Scale, and the Japanese version of the Developmental Coordination Disorder Questionnaire were variables of interest. To test hypotheses about the region-specific effects of these variables, the estimates were compared using 2 linear contrasts (positive or negative correlation). In the SPM5 analyses, values of P < .05 were statistically significant after adjustment for the false discovery rate in the whole-brain multiple comparisons.

In the VOI-based analyses, we tested the main effect of the diagnosis of ASD on [11C](R)-PK11195 BP values derived from 13 brain regions using 2-way analysis of variance, in which statistical significance was set at P < .05. For comparisons of clinical variables between subgroups of ASD subjects, a Mann-Whitney test was performed. To assess the differences in segmented brain volumes between groups in the voxel-based morphometry analysis, we conducted a multivariate analysis of covariance using PASW software with group (ASD and control) as a between-subject factor, segmented brain regional absolute volume (GM, WM, and CSF) as a within-subject factor, and intracranial volume as a covariate. The statistical significance level was set at P < .05. Second, for the GM analysis, the normalized, modulated, and smoothed GM image segments in each group were entered into a voxel-wise 2-sample t test analysis in SPM5. An absolute threshold mask of 0.30 was used to avoid possible edge effects around the border between GM and WM. The statistical threshold was set at P < .05 after the false discovery rate correction. Data were presented as mean (SD).

RESULTS

Characteristics of all the subjects are summarized in Table 1. There was no significant difference in age or IQ between the 2 groups.

CORRELATION BETWEEN [11C](R)-PK11195 BP AND SYMPTOMS IN ASD

Relationships between the regional changes in [11C](R)-PK11195 BP values and the clinical features of ASD subjects were evaluated by voxel-based exploratory correlation analyses using SPM5. There was no voxel for which significant correlations were observed between [11C](R)-
PK11195 BP and the scores on the Faux Pas Test, Yale-Brown Obsessive Compulsive Scale, ADI-R, ADOS, or the Japanese version of the Developmental Coordination Disorder Questionnaire after the correction of whole-brain multiple comparisons (data not shown).

In the VOI-based analysis, we also conducted correlation analyses between $[^{11}C](R)$-PK11195 BP in each VOI and clinical valuables, and we found no significant correlations. We divided the ASD group into 2 subgroups, a High-BP and Not-High-BP group, on the basis of the

---

**Figure 1.** Results of positron emission tomography image analyses in a healthy control subject and a subject with autism. A, Scattergrams showing the time-activity curves of radiocarbon ($[^{11}C]$)-labeled $(R)$-(1-[2-chloropheny]N-methyl[N-[1-methyl(propyl)]-3 isoquinoline carboxamide) $([^{11}C](R)$-PK11195) for regions of interest in the cerebellum, midbrain, and thalamus in a subject with autism spectrum disorder (ASD) and a control subject. B, Magnetic resonance imaging–positron emission tomography fusion parametric images of $[^{11}C](R)$-PK11195 binding potential in a subject with ASD and a control subject. The left brain is shown on the right. The color bar indicates a level of binding potential.
Table 2. Results of the Whole-Brain Voxel-Based Statistical Parametric Mapping Analyses of $^{[11]}$C($R$)-PK11195 Binding Potential: Increase in Binding in the Subjects With ASD$^a$

<table>
<thead>
<tr>
<th>Brain Regions</th>
<th>Coordinates</th>
<th>Voxel Level</th>
<th>Corrected $P$ Value</th>
<th>$z$ Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebellum</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left lobuli 7, 8, and 9</td>
<td>$-10$</td>
<td>$-58$</td>
<td>$-38$</td>
<td>.03</td>
</tr>
<tr>
<td>Right lobuli 7 and 8</td>
<td>$32$</td>
<td>$-76$</td>
<td>$-48$</td>
<td>.04</td>
</tr>
<tr>
<td>Brainstem (midbrain and pons)</td>
<td>$10$</td>
<td>$-38$</td>
<td>$-42$</td>
<td>.03</td>
</tr>
<tr>
<td>Frontal region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left middle frontal gyrus, BA10, BA46</td>
<td>$-44$</td>
<td>$50$</td>
<td>$12$</td>
<td>.03</td>
</tr>
<tr>
<td>Left orbitofrontal cortex, BA11</td>
<td>$-8$</td>
<td>$48$</td>
<td>$-4$</td>
<td>.03</td>
</tr>
<tr>
<td>Right orbitofrontal cortex, BA47</td>
<td>$14$</td>
<td>$30$</td>
<td>$-16$</td>
<td>.03</td>
</tr>
<tr>
<td>Temporal region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left superior temporal gyrus, BA22</td>
<td>$-52$</td>
<td>$-28$</td>
<td>$4$</td>
<td>.03</td>
</tr>
<tr>
<td>Right superior temporal gyrus, BA22</td>
<td>$50$</td>
<td>$-20$</td>
<td>$-6$</td>
<td>.03</td>
</tr>
<tr>
<td>Left fusiform gyrus, BA37</td>
<td>$-48$</td>
<td>$-60$</td>
<td>$-14$</td>
<td>.03</td>
</tr>
<tr>
<td>Right fusiform gyrus, BA37</td>
<td>$38$</td>
<td>$-58$</td>
<td>$-16$</td>
<td>.03</td>
</tr>
<tr>
<td>Parietal region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right parietal cortex, BA40</td>
<td>$28$</td>
<td>$-48$</td>
<td>$54$</td>
<td>.03</td>
</tr>
<tr>
<td>Limbic region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left anterior cingulate cortex, BA32</td>
<td>$-6$</td>
<td>$38$</td>
<td>$18$</td>
<td>.03</td>
</tr>
<tr>
<td>Right anterior cingulate cortex, BA32</td>
<td>$18$</td>
<td>$10$</td>
<td>$46$</td>
<td>.04</td>
</tr>
<tr>
<td>Subcortical region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corpus callosum</td>
<td>$-2$</td>
<td>$-26$</td>
<td>$16$</td>
<td>.03</td>
</tr>
</tbody>
</table>

Abbreviations: ASD, autism spectrum disorder; BA, Brodmann area; $^{[11]}$C($R$)-PK11195, radioactive carbon-labeled ($R$)-1-(2-chlorophenyl)-N-methyl-N-[1-methylpropyl]-3 isoquinoline carboxamide.

$^a$The significance thresholds at the voxel cluster levels were $P < .05$ after false discovery rate correction for multiple comparisons across the whole brain. Coordinates are given in millimeters based on the Montreal Neurological Institute brain template. Each location is a peak within a cluster (defined as the voxel with highest $z$ score).
than 2 SDs higher than the mean BP of controls. The number of ASD subjects who had BPs that were more than 2 SDs higher than the mean value of the controls was 6 for the VOI in the midbrain, 10 for the VOI in the right orbitofrontal cortex, and 8 for the VOI in the right anterior cingulate cortex. Subjects with ASD who exhibited high BPs in at least 3 of the 4 VOIs were classified into a High-BP group (n = 7), and the remaining subjects were classified into a Not-High-BP group (n = 13). When clinical variables were compared between the High-BP and Not-High-BP groups, statistically significant differences were observed for the social scores of the ADI-R (U = 19.0, P = .04) and the ADOS (U = 13.0, P = .01) (Figure 5), suggesting that social disabilities might be more severe in the High-BP group.

The absolute volumes of the segmented brain regions were estimated in the control and ASD groups (GM: 676.3 [50.3] vs 705.8 [78.2] [control vs ASD]; WM: 421.7 [42.3] vs 439.7 [48.4]; CSF: 405.1 [47.1] vs 426.0 [50.2]; and intracranial volume: 1503.1 [123.7] vs 1571.5 [161.7]). The multivariate analysis of covariance revealed no significant differences in volume between the 2 groups (GM: F1,37 = 0.006, P = .94; WM: F1,37 = 0.209, P = .65; CSF: F1,37 = 0.036, P = .85). A voxelwise 2-sample t test analysis of normalized and smoothed

Figure 3. Regional brain [11C](R)-PK11195 binding potential in the autism spectrum disorder (ASD) and control group. Subjects with ASD had significantly higher [11C](R)-PK11195 binding potentials than those of controls (F12,456 = 24.59, P < .001). Error bars represent the SEM. Cx indicates cortex; Gy, gyrus; L, left; and R, right.

Figure 4. Scatterplot of regional [11C](R)-PK11195 binding potential in the autism spectrum disorder (ASD) and control groups in 4 spherical volumes of interest placed over the left cerebellum, midbrain, right orbitofrontal cortex, and right anterior cingulate cortex.

Figure 5. Comparison of social domain scores from Autism Diagnostic Interview–Revised (ADI-R) (A) and Autism Diagnostic Observation Schedule (ADOS) (B) between the High-Binding Potential (BP) and Not-High-BP subgroups in subjects with autism spectrum disorder. *P = .03 and †P = .006.
GM images revealed no significant differences in GM volume between the 2 groups (data not shown).

COMMENT

Our PET measurements revealed that young adults with ASD had significantly increased $[^{11}C](R)$-PK11195 BP, a representative measure of the activation of microglia, in a wide range of brain areas, including the cerebellum, brainstem, anterior cingulate cortex, frontal cortex (orbitofrontal and midfrontal), temporal cortex (superior temporal and fusiform), parietal cortex, and corpus callosum. The microglial activation was greater in the ASD group than in the control group across all regions tested, although the most prominent increase was evident in the cerebellum. To our knowledge, this is the first in vivo evidence of the presence of excessive microglial activation in ASD subjects, and these findings support the contention that microglial activation may play a role in the pathogenesis of ASD.

When we performed a VOI-based analysis on the $[^{11}C](R)$-PK11195 BPs for different brain regions associated with microglial activation, the pattern of distribution of $[^{11}C](R)$-PK11195 BP values throughout the VOIs was quite similar between the ASD and control subjects. The similar distribution of regionally activated microglia in the ASD and control groups may indicate the augmented but not altered microglial activation in the brain in the ASD subjects. Resident microglia, which are embryonic and fetal in origin, can be replenished intrinsically and do not require significant turnover from circulating blood progenitors (monocytes) (see also the review by Chan et al). Under pathologic conditions, however, microglia in neonates and adults are considered to derive from circulating blood monocytes originating primarily within the bone marrow. In brain tissues from children and adults with ASD, macrophage chemoattractant protein-1, which can facilitate the infiltration and accumulation of blood monocytes in the brain, is greatly increased. It is also possible that microglia might respond to prolonged aberrant neuronal functioning in the ASD adults, providing trophic support to damaged cells or engaging in synaptic stripping to protect against excitotoxicity. Taken together, the excessive activation of microglia in ASD subjects could begin in the prenatal period and last until adulthood. However, we propose that the critical period for the occurrence of excessive activation of microglia as a possible pathogenic factor for ASD may be during prenatal and early postnatal development of the brain because symptoms of ASD are manifested very early in life, typically by 3 years of age. To better understand the detailed mechanism underlying the long-running microglial activation, further studies, including experiments in animal models, may be helpful.

In the present PET assessment, young adults with ASD showed a prominent activation of microglia in the cerebellum. The cerebellum has been one of the foci of postmortem studies of autistic children and adults. Of the 30 postmortem cases of autism in which the cerebellum has been studied, 22 (73%) showed a reduced number of Purkinje cells, particularly in the hemispheres. Pathologic abnormalities have been observed in both childhood and adult cases, with and without a history of seizures or medication usage. It is not known whether cerebellar lesions might have been present in the high-functioning young adults with ASD recruited for this study. Nonetheless, cerebellar activation of the microglia may reflect an association with cerebellar pathologic abnormalities, because when N-acetylaspartate, a putative marker of neuronal loss, was assessed by proton magnetic resonance spectroscopy, levels were significantly decreased in high-functioning adults with ASD. An in vitro study has demonstrated that microglial activation can promote the death of developing Purkinje cells via reactive oxygen species, however, it remains unclear whether this microglia-mediated mechanism would apply in cases of ASD.

The voxel-based correlation analysis failed to find a cluster in which $[^{11}C](R)$-PK11195 BP correlated significantly with any of the clinical features evaluated by the Faux Pas Test, Yale-Brown Obsessive Compulsive Scale, ADI-R, and ADOS. However, when ASD subjects were divided into High-BP and Not-High-BP subgroups before being entered into the VOI-based analysis, social disabilities as assessed by ADI-R and ADOS in the High-BP subgroup were significantly more severe than in the Not-High-BP subgroup. The results suggest that ASD subjects carrying more microglial activation may be more impaired in their cognitive skills. In a previous study, immune abnormalities in peripheral blood from severely affected children with ASD, especially the regressive type of autism, appeared to correlate with the disturbance of cognitive skills. Considering the positive observation of the VOI-based analysis and the previous data in the ASD children with regression, the failure of the voxel-based correlation analysis was probably due to the selection of the ASD subjects, all of whom were high-functioning ASD subjects with no regression. Namely, the subject selection may have been inappropriate for comparison with studies of severely affected cases. The small subject population may be another reason for the lack of voxel-based correlation analysis. In this study, there was no correlation in the cerebellum between the $[^{11}C](R)$-PK11195 BP and motor coordination as assessed by the Developmental Coordination Disorder Questionnaire. Again, the selection of the high-functioning subjects and the small sample size may have contributed to the absence of correlation. Although there was no correlation of microglial activation with any of the clinical features, this could not exclude the recently emerging evidence that microglia play a crucial role in monitoring and maintaining synapses in the uninjured brain. During development, microglia actively engulf synaptical material and play a major role in synaptic pruning. Microglial activation might have led to impairment of synaptic function in the corresponding brain regions being associated with clinical features in ASD.

Several limitations of our study bear mention. Our study was performed on a population basis and the subject group consisted entirely of high-functioning ASD subjects. That is, this study did not include ASD subtypes in which immunologic abnormality may be more prominent, although greater microglial activations are more
likely to occur in more severe subtypes. Another potential weakness was the nature of the tracer used in this study, which has a significant nonspecific binding. Future studies on a wider range of autistic phenotypes using a new ligand with more specificity would be warranted.

In conclusion, the present PET measurements revealed marked activation of microglia in multiple brain regions of young adults with ASD. The results strongly support the contention that immune abnormalities contribute to the etiology of ASD. The similar patterns of distribution of regionally activated microglia in these ASD and control groups may indicate the augmented but not altered microglial activation in the brain in the ASD subjects.

Submitted for Publication: November 22, 2011; final revision received March 27, 2012; accepted March 30, 2012.

Published Online: November 26, 2012. doi:10.1001/jamapsychiatry.2013.272

Author Affiliations: Research Center for Child Mental Development (Drs Suzuki, Sugihara, Omata, Tsuchiya, and Mori and Ms Matsumoto), United Graduate School of Child Development (Drs Suzuki, Ouchi, and Tsuchiya), Molecular Imaging Frontier Research Center (Dr Ouchi), Departments of Psychiatry and Neurology (Drs Nakamura, Takebayashi, Iwata, and Mori) and Child and Adolescent Psychiatry (Dr Sugiyama), Hamamatsu University School of Medicine, and Positron Medical Center, Hamamatsu Medical Center (Dr Ouchi and Mr Futatsubashi), Hamamatsu; Koujin Hospital, Nagoya (Dr Yoshihara); and Faculty of Sociology, Chukyo University, Toyota (Mr Tsujii), Japan.

Correspondence: Norio Mori, MD, PhD, Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan (morin@hama-med.ac.jp).

Author Contributions: Drs Suzuki and Sugihara contributed equally to this work.

Conflict of Interest Disclosures: None reported.

Funding/Sponsor: This work was supported by the Strategic Research Program for Brain Sciences (“Integrated research on neuropsychiatric disorders”) and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, and by the Research on Brain Science Funds from the Ministry of Health, Labour, and Welfare, Japan.

Role of the Sponsors: These funding sources played no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

Additional Contributions: We are grateful to Toshihiko Kanno, MS, Etsuji Yoshikawa, MS, Wataru Ishida, MA, Taro Takahashi, PhD, Utako Matsuo, MA, Kaori Inaho, MA, and Manami Ogawa, MA, for their excellent assistance.

REFERENCES


